A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma

Authors :: Joseph P. Erinjeri
Mrinal M. Gounder
Sandra P. D'Angelo
Aimee M. Crago
Ciara Marie Kelly
Charlotte E. Ariyan
Timothy G. Bowler
Li-Xuan Qin
Ping Chi
Mercedes M. Condy
Mary Louise Keohan
Rodrigo Ramella Munhoz
William D. Tap
Cristina R. Antonescu
Sam S. Yoon
Reena Dholakia
Mark A. Dickson
Sinchun Hwang
Samuel Singer
Source :: Journal of Clinical Oncology. 36:11516-11516
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 11516Background: T-VEC is an oncolytic immunotherapy derived from HSV type-1 that is modified to selectively replicate within tumors and produce GM-CSF. Pembrolizumab (P) demonstrated activity in s...

Subjects :: 0301 basic medicine
Cancer Research
business.industry
medicine.medical_treatment
Phases of clinical research
Pembrolizumab
Immunotherapy
Oncolytic virus
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
Medicine
In patient
Metastatic sarcoma
Talimogene laherparepvec
business

Full Text Access

Tools